Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Nov 16, 2020
Date Accepted: Jan 20, 2021
Date Submitted to PubMed: Jan 21, 2021
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Central Asia SARS-CoV-2 Surveillance: A Longitudinal Trend Analysis
ABSTRACT
Background:
SARS-CoV-2, the virus that caused the COVID-19 global pandemic, has severely impacted Central Asia, resulting in a high caseload and deaths that varied by country in Spring 2020. The varying severity of the pandemic is explained by differences in prevention efforts in the form of public health policy, adherence to those guidelines, as well as socio-cultural, climate, and population characteristics. The second wave of the COVID-19 currently is breaching the borders of Europe. Public health surveillance is necessary to inform policy and guide leaders; however, existing surveillance explains past transmissions obscuring shifts in the pandemic, increases in infection rates, and the persistence in the transmission of COVID-19.
Objective:
The goal of this study is to provide enhanced surveillance metrics for COVID-19 transmission that account for shifts in the pandemic, week over week, speed, acceleration, jerk and persistence, to better understand country risk for explosive growth and those who are managing the pandemic successfully. Existing surveillance, coupled with our dynamic metrics of transmission, will inform health policy to control the COVID-19 pandemic until an effective vaccine is developed and provides novel metrics to measure the transmission of disease.
Methods:
Using a longitudinal trend analysis study design, we extracted 60 days of COVID data from public health registries. We use an empirical difference equation to measure the daily number of cases in the Central Asia region as a function of the prior number of cases, the level of testing, and weekly shift variables based on a dynamic panel model that was estimated using the generalized method of moments (GMM) approach by implementing the Arellano-Bond estimator in R.
Results:
COVID-19 transmission rates were tracked for the weeks of 9/30-10/06 and 10/07 to 10/13 in Central Asia. The region averaged 11,730 new cases per day for the week ending in 10/06 and 14,514 for the week ending in 10/13. Infection rates increased across the region from 4.74 per 100,000 in the population to 5.66. Infection rates varied by country. Russia and Turkey had the highest seven-day moving averages in the region, at 9,836 and 1,469 respectively for the week of 10/06 and 12,501 and 1,603 respectively for the week of 10/13. Russia has the fourth highest speed in the region and continues to have positive acceleration, driving the negative trend for the entire region as the largest country by population. Armenia is experiencing explosive growth of COVID-19, with an infection rate of 13.73 for the week of 10/06 quickly jumping to 25.19, the highest in the region, the following week. The pandemic speed in Armenia, consistent with the infection rate trajectory, increased from 15.4 to 21.7, with an acceleration increase from 0.4 to 1.6 meaning acceleration has increased fourfold. The region overall is experiencing increases in seven-day moving average of new cases, infection, rate and speed, with continued positive acceleration and no sign of a reversal in sight.
Conclusions:
The rapidly evolving COVID-19 pandemic requires novel dynamic surveillance metrics in addition to static metrics to effectively analyze pandemic trajectory and control spread. Policymakers need to know the magnitude of transmission rates, how quickly they are accelerating, and how previous cases are impacting current caseload due to a lag effect. These metrics applied to Central Asia suggest that the region is trending negatively, primarily due to minimal restrictions in Russia. Russia already has the fourth highest number of cases in the world and current metrics suggest Russia will continue on that trajectory. Clinical Trial: NA
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.